Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketorolac + lidocaine versus articaine infiltration to improve inferior alveolar nerve block success in mandibular molars with symptomatic irreversible pulpitis
IRCT20251018067669N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ketorolac, lidocaine and articaine in irreversible pulpitis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Success of the inferior alveolar nerve block and Failure of the inferior alveolar nerve block. Started Jan 2026; status: completed.
02
Drugs
ketorolaclidocainearticaine
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on IRCT20251018067669N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251018067669N1.